VIRMA and cancer: In OSCC, VIRMA regulated PGK1 via the YTHDF1/m6A-dependent pathway, leading to increased glucose uptake, lactate production, and extracellular acidification rate (ECAR), with decreased oxygen consumption rate (OCR), ultimately enhancing the glycolytic rate and capacity of cancer cells [33].